Coherus Oncology, Inc. current report, 17 May 2022

Full document

Coherus Biosciences, Inc. 8-K Summary

Business Context and Reporting Period

This Form 8-K reports on the 2022 Annual Meeting of Stockholders held virtually on May 17, 2022. The record date for the meeting was March 21, 2022, with 77,329,578 shares of common stock outstanding. A total of 65,215,669 shares were voted on the three proposals presented.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate governance and voting results.

Material Changes and Voting Results

The following proposals were voted upon by stockholders:

  • Proposal 1 (Election of Directors): Stockholders elected Ali Satvat and Mark D. Stolper as Class II directors to serve until the 2025 annual meeting.
    • Ali Satvat: 50,260,233 votes FOR; 9,967,425 votes WITHHELD.
    • Mark D. Stolper: 58,410,139 votes FOR; 1,817,519 votes WITHHELD.
  • Proposal 2 (Ratification of Auditors): Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
    • Results: 64,930,458 votes FOR; 195,114 votes AGAINST; 90,097 votes ABSTAIN.
  • Proposal 3 (Say-on-Pay Frequency): Stockholders voted on the preferred frequency for advisory votes on executive compensation.
    • Results: The majority (44,276,605 votes) selected a 1-year frequency. 15,606,803 votes selected 3 years, and 106,827 votes selected 2 years.

Guidance, Outlook, and Risks

The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.

Key Facts for Investor Verification

  • Verify the tenure of newly elected directors Ali Satvat and Mark D. Stolper (until 2025).
  • Confirm the appointment of Ernst & Young LLP as the auditor for the 2022 fiscal year.
  • Note the stockholder preference for annual (1-year) advisory votes on executive compensation.
  • Review the Definitive Proxy Statement on Schedule 14A (filed April 4, 2022) for detailed background on the proposals.